Navigation Links
Through 2018, Five New Drugs Will Launch for the Treatment of Myelodysplastic Syndromes

BURLINGTON, Mass., Feb. 6, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, through 2018, five new drugs will launch for the treatment of myelodysplastic syndromes (MDS), three of which are expected to offer much-needed second-line therapeutic options in the hypomethylating agent (HMA)-refractory higher-risk MDS population. Currently, there is only one curative treatment for MDS -- allogeneic hematopoietic stem cell transplant (HSCT). However, old age and poor general performance status classifies approximately 75 percent of patients as ineligible for this treatment.

(Logo: )

Between 2004 and 2006, the U.S. MDS market expanded when the first drug therapy options were approved for the indication -- azacitidine (Celgene's Vidaza), lenalidomide (Celgene's Revlimid) and decitabine (Eisai/MGI Pharma's Dacogen). No new therapies have been approved in the United States for MDS since 2006; only azacitidine has been approved for MDS in Europe, although experts believe an EU approval for lenalidomide is imminent.

According to Niche Markets and Rare Diseases: Myelodysplastic Syndromes, azacitidine is the leading therapeutic option for the disease in both the U.S. and Europe. Decision Resources anticipates expansion of MDS therapeutic options with the approval of five drugs between 2014-2018: oral azacitidine for transfusion-dependent lower-risk MDS; Onconova/Baxter's intravenous formulation of rigosertib (Estybon) for HMA-refractory higher-risk MDS; Merck's vorinostat (Zolinza) for combination therapy with azacitidine in higher-risk MDS; Cyclacel's oral sapacitabine for HMA-refractory higher-risk MDS; and GlaxoSmithKline's eltrombopag (Revolade) for HMA-refractory higher-risk MDS, with a focal goal of reducing thrombocytopenia. Onconova also has an oral formulation of rigosertib in development for lower-risk patients.

"The near-term MDS drug market will grow modestly as lenalidomide obtains approval in Europe, but the next wave of noteworthy market growth will come between 2014 and 2018," said Decision Resources Vice President Kim Crowell . "While experts acknowledge that the approvals of azacitidine and lenalidomide were groundbreaking, they also report significant remaining unmet need in MDS. Citing the dearth of second-line options for higher-risk MDS patients, experts are hopeful that several Phase II and III drugs will provide valuable alternative therapeutic options, although they do not expect any drug during the next decade to completely shift or uproot the MDS therapeutic landscape. Improving overall survival, without sacrificing quality of life, is the key therapeutic goal in higher risk MDS patients, while functional quality of life via hematologic improvement is the primary goal in lower-risk patients."

About Myelodysplastic Syndromes

Myelodysplastic Syndromes is offered as part of Decision Resources' Niche Markets and Rare Diseases service. Each report assesses opportunity in a select drug market across the United States, France, Germany, Italy, Spain and the United Kingdom. The report provides detailed coverage of patient populations, current therapies, unmet needs and emerging therapies, and includes primary research with country-specific thought leaders.

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Breakthrough Procedure Provides Relief for Acid Reflux
2. The Treatment Landscape for Thyroid Carcinoma Will Change Dramatically Through 2021
3. Sanofi Launches Breakthrough Technology for Cardiovascular and Vascular Surgery Procedures
4. Inherited Orphan Blood Disorders Therapeutics Market to 2019 - Breakthrough Drugs Remain Elusive Against Backdrop of High Unmet Need
5. Executives guide entrepreneurs through science business maze
6. Seeing Life Through Many Lenses: Different Ophthalmic Lenses for Different Lifestyles
7. Brazilian, Indian and Chinese Orthopedic Markets to See Strong Growth Through 2017
8. Breakthrough Research Could Create Sea Change in Global HIV Diagnosis: New Handheld Mobile Device Performs Laboratory-Quality HIV Testing
9. Maximizing the Effectiveness of Market Research Groups through Outsourcing and Automation
10. New Breakthrough Treatment For Evaporative Dry Eye Disease Introduced By Dry Eye Specialist, Mark R. Mandel, M.D.
11. Elseviers Clinical Pharmacology Now Accessible Through Elsevier Infobutton
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015 AAIPharma ... planned investment of at least $15.8  Million to ... Wilmington, NC . The expansion will ... to meet the growing demands of the pharmaceutical ... site expansion will provide up to 40,000 ...
(Date:11/25/2015)... Allergan plc (NYSE: AGN ) today announced that it ... State Attorney General,s Office to end the litigation ... with the Attorney General over the decision of Forest Laboratories, ... the now generic version of memantine immediate release tablets.  Under ... its counterclaims against New York , and ...
(Date:11/25/2015)... USP 800 applies to all healthcare ... pharmacy technicians, nurses, physicians, physician assistants, home healthcare ... covers all entities which store, prepare, transport, or ... institutions, patient treatment clinics, physicians, practice facilities, and ... --> What is the purpose of USP ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... ... On November 23rd 2015 Cozy Products, a division of Bird-X ... Products explains what this means for business moving forward. , The Tri Lite heater ... model: to sell personal heaters that reduce energy consumption, are economical and keep people ...
(Date:11/25/2015)... ... November 25, 2015 , ... SCOTTSDALE, AZ) ... plastic surgeon specializing in both surgical and non-surgical treatments, announced the expansion of ... Hobgood Facial Plastic Surgery. , Highly trained and nationally recognized for his ...
(Date:11/25/2015)... ... November 25, 2015 , ... Brillianteen, McGaw ... and learning in its 65th Anniversary Brillianteen Revue, scheduled for March 4-6, 2016. ... For 65 years, Brillianteen has been a treasured tradition for numerous families in ...
(Date:11/25/2015)... ... , ... “While riding the bus, I saw a passenger in a wheelchair ... to be a convenient and comfortable way to protect them from bad weather, so ... safely travel during cold or inclement weather. In doing so, it ensures that the ...
(Date:11/25/2015)... Missouri (PRWEB) , ... November 25, 2015 , ... ... HEAL, will provide scholarships for people struggling with eating disorders as a result ... from the second annual event, held at Fox Run Golf Club in Eureka, ...
Breaking Medicine News(10 mins):